| | |
Affected area
|
MFI
| |
|---|
|
Biomarker candidate
|
Control vs. cohort
|
AUC
|
95% Confidence interval
|
Sensit. at 90% specif.
|
AUC
|
95% Confidence interval
|
Sensit. at 90% specif.
| |
|---|
|
CD38 and CD11b
|
RA
|
0.77
|
0.61
|
-
|
0.94
|
46.82
|
0.77
|
0.61
|
-
|
0.94
|
44.95
| |
| |
RA(+)
|
0.69
|
0.48
|
-
|
0.89
|
28.45
|
0.70
|
0.49
|
-
|
0.90
|
29.12
| |
| |
RA(++)
|
0.97
|
0.87
|
-
|
1.00
|
91.98
|
0.94
|
0.83
|
-
|
1.00
|
83.20
| |
|
CD304 and CD64
|
RA
|
0.84
|
0.71
|
-
|
0.98
|
66.16
|
0.79
|
0.63
|
-
|
0.95
|
65.08
| |
| |
RA(+)
|
0.78
|
0.59
|
-
|
0.96
|
51.07
|
0.70
|
0.48
|
-
|
0.92
|
49.88
| |
| |
RA(++)
|
1.00
|
1.00
|
-
|
1.00
|
100.00
|
1.00
|
1.00
|
-
|
1.00
|
100.00
| |
|
CD90 and CD29
|
RA
|
0.81
|
0.67
|
-
|
0.96
|
56.42
|
0.83
|
0.68
|
-
|
0.97
|
55.84
| |
| |
RA(+)
|
0.86
|
0.72
|
-
|
1.00
|
70.98
|
0.86
|
0.72
|
-
|
1.00
|
66.31
| |
| |
RA(++)
|
0.67
|
0.42
|
-
|
0.92
|
9.24
|
0.75
|
0.49
|
-
|
1.00
|
35.48
| |
|
HLA-DR and CD90
|
RA
|
0.87
|
0.74
|
-
|
0.99
|
65.46
|
0.87
|
0.74
|
-
|
0.99
|
66.53
| |
| |
RA(+)
|
0.89
|
0.75
|
-
|
1.00
|
73.92
|
0.90
|
0.77
|
-
|
1.00
|
75.96
| |
| |
RA(++)
|
0.83
|
0.61
|
-
|
1.00
|
53.85
|
0.79
|
0.54
|
-
|
1.00
|
51.55
| |
|
HLA-DR and CD29
|
RA
|
0.86
|
0.74
|
-
|
0.99
|
63.02
|
0.88
|
0.76
|
-
|
1.00
|
69.08
| |
| |
RA(+)
|
0.88
|
0.75
|
-
|
1.00
|
69.96
|
0.93
|
0.83
|
-
|
1.00
|
81.57
| |
| |
RA(++)
|
0.84
|
0.66
|
-
|
1.00
|
44.26
|
0.76
|
0.49
|
-
|
1.00
|
47.12
| |
|
CD29, CD90, and HLA-DR
|
RA
|
0.90
|
0.79
|
-
|
1.00
|
70.64
|
0.90
|
0.79
|
-
|
1.00
|
72.25
| |
| |
RA(+)
|
0.91
|
0.79
|
-
|
1.00
|
78.20
|
0.95
|
0.86
|
-
|
1.00
|
83.07
| |
| |
RA(++)
|
0.87
|
0.69
|
-
|
1.00
|
58.44
|
0.71
|
0.46
|
-
|
0.97
|
56.13
| |
- Listed panels of potential biomarkers were labeled simultaneously by the respective antibodies on synovial tissue and analyzed with LSC. Data were obtained with ROC analysis. Bold, AUC > 0.85.
